Decompensated heart failure

ABSTRACT Heart failure is a disease with high incidence and prevalence in the population. The costs with hospitalization for decompensated heart failure reach approximately 60% of the total cost with heart failure treatment, and mortality during hospitalization varies according to the studied population, and could achieve values of 10%. In patients with decompensated heart failure, history and physical examination are of great value for the diagnosis of the syndrome, and also can help the physician to identify the beginning of symptoms, and give information about etiology, causes and prognosis of the disease. The initial objective of decompensated heart failure treatment is the hemodynamic and symptomatic improvement preservation and/or improvement of renal function, prevention of myocardial damage, modulation of the neurohormonal and/or inflammatory activation and control of comorbidities that can cause or contribute to progression of the syndrome. According to the clinical-hemodynamic profile, it is possible to establish a rational for the treatment of decompensated heart failure, individualizing the proceedings to be held, leading to reduction in the period of hospitalization and consequently reducing overall mortality.

[1]  A. Burger,et al.  Effect of nesiritide (human b-type natriuretic peptide) and dobutamine on heart rate variability in decompensated heart failure. , 2004, American heart journal.

[2]  S. Gottlieb,et al.  Diuretics: Still the mainstay of treatment , 2008, Critical care medicine.

[3]  H. Krumholz,et al.  Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? , 2002, Journal of cardiac failure.

[4]  C. O'connor,et al.  Vasopressin: a new target for the treatment of heart failure. , 2003, American heart journal.

[5]  C. F. Lin,et al.  Comparison of sublingual captopril, nifedipine and prazosin in hypertensive emergencies during hemodialysis. , 1993, Nephron.

[6]  K. Adams,et al.  Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, American heart journal.

[7]  R. Califf,et al.  Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. , 2002, JAMA.

[8]  C. O'connor,et al.  Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. , 2003, The American journal of cardiology.

[9]  Eiser Ar,et al.  Phlebotomy for pulmonary edema in dialysis patients. , 1997 .

[10]  A. Cohen-Solal,et al.  Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. , 2007, Journal of the American College of Cardiology.

[11]  P. Mcdermott,et al.  Effect of ED management on ICU use in acute pulmonary edema. , 1999, The American journal of emergency medicine.

[12]  A. Cohen-Solal,et al.  Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. , 2007, JAMA.

[13]  L. Rohde,et al.  I Latin American Guidelines for the Assessment and Management of Decompensated Heart Failure. , 2005, Arquivos brasileiros de cardiologia.

[14]  B. Pitt,et al.  Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[15]  L. Stevenson,et al.  Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. , 2003, Journal of the American College of Cardiology.

[16]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[17]  G. Keating,et al.  Nesiritide: a review of its use in acute decompensated heart failure. , 2003, Drugs.

[18]  W. Abraham,et al.  Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.

[19]  V. Issa,et al.  Solução salina hipertônica para prevenção de insuficiência renal em pacientes com insuficiência cardíaca descompensada e hiponatremia , 2007 .

[20]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[21]  T. LeJemtel,et al.  Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. , 2000, The New England journal of medicine.

[22]  G. Fonarow.  Approach to the management of diabetic patients with heart failure: role of thiazolidinediones. , 2004, American heart journal.

[23]  J. Burnett,et al.  Brain Natriuretic Peptide Enhances Renal Actions of Furosemide and Suppresses Furosemide-Induced Aldosterone Activation in Experimental Heart Failure , 2004, Circulation.

[24]  A. Mebazaa,et al.  Algorithm for therapeutic management of acute heart failure syndromes , 2007, Heart Failure Reviews.

[25]  K. Aaronson,et al.  Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. , 2005, JAMA.

[26]  A. Cohen-Solal,et al.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). , 2005, European heart journal.

[27]  Salim Yusuf,et al.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients , 2000, The Lancet.

[28]  D. Schwartz,et al.  The Interaction between Heart Failure, Renal Failure and Anemia – The Cardio-Renal Anemia Syndrome , 2004, Blood Purification.

[29]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[30]  C. O'connor,et al.  Anemia as a risk factor and therapeutic target in heart failure. , 2004, Journal of the American College of Cardiology.

[31]  P. Poole‐Wilson,et al.  Should beta‐blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET , 2007, European journal of heart failure.

[32]  R. Califf,et al.  Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). , 1999, American heart journal.

[33]  W. Frishman,et al.  Fenoldopam: A New Dopamine Agonist for the Treatment of Hypertensive Urgencies and Emergencies , 1998, Journal of clinical pharmacology.

[34]  Peter Buser,et al.  BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. , 2009, JAMA.

[35]  Y. Moshkovitz,et al.  Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema , 1998, The Lancet.

[36]  Paul W Armstrong,et al.  Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes: Insights From a Cohort of 12 065 Patients With New-Onset Heart Failure , 2003, Circulation.

[37]  R. Vanholder,et al.  Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. , 2001, American Journal of Medicine.

[38]  M. Levitt.  A prospective, randomized trial of BiPAP in severe acute congestive heart failure. , 2001, The Journal of emergency medicine.

[39]  J. Moran,et al.  Effect of non-invasive positive pressure ventilation (NIPPV) on mortality in patients with acute cardiogenic pulmonary oedema: a meta-analysis , 2006, The Lancet.

[40]  A. Maisel,et al.  B-Type Natriuretic Peptide: The Level and the Drug— Partners in the Diagnosis and Management of Congestive Heart Failure , 2004 .

[41]  H. Crijns,et al.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation , 2002 .

[42]  J. Papp,et al.  STEERING COMMITTEE AND INVESTIGATORS OF THE LEVOSIMENDAN INFUSION VERSUS DOBUTAMINE (LIDO) STUDY. EFFICACY AND SAFETY OF INTRAVENOUS LEVOSIMENDAN COMPARED WITH DOBUTAMINE IN SEVERE LOWOUTPUT HEART FAILURE (THE LIDO STUDY): A RANDOMISED DOUBLEBLIND TRIAL , 2002 .

[43]  K. Dickstein,et al.  [Executive summary of the guidelines on the diagnosis and treatment of acute heart failure]. , 2005, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[44]  Ali Ahmed,et al.  Impact of atrial fibrillation on mortality and readmission in older adults hospitalized with heart failure , 2004, European journal of heart failure.

[45]  L. F. Seguro,et al.  Insuficiência cardíaca descompensada na unidade de emergência de hospital especializado em cardiologia , 2008 .

[46]  C. O'connor,et al.  Diuretic resistance predicts mortality in patients with advanced heart failure. , 2002, American heart journal.

[47]  L. Lenert,et al.  Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. , 2001, Journal of the American College of Cardiology.

[48]  D. Levy,et al.  Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. , 1994, JAMA.

[49]  J. Heywood,et al.  Effect of Nesiritide on Length of Hospital Stay in Patients with Decompensated Heart Failure , 2004, Journal of cardiovascular pharmacology and therapeutics.

[50]  A. Collins,et al.  Impact of congestive heart failure, chronic kidney disease, and anemia on survival in the Medicare population. , 2004, Journal of cardiac failure.

[51]  M. Nieminen,et al.  Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). , 2002, European heart journal.

[52]  R. Bonow,et al.  Chronic heart failure in the United States: a manifestation of coronary artery disease. , 1998, Circulation.

[53]  H. Ni.  Prevalence of self-reported heart failure among US adults: results from the 1999 National Health Interview Survey. , 2003, American heart journal.

[54]  R. Vasan,et al.  The progression from hypertension to congestive heart failure. , 1996, JAMA.

[55]  M. Gheorghiade,et al.  The role of the kidney in heart failure. , 2012, European heart journal.

[56]  M. Tonelli,et al.  The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. , 2004, Journal of the American College of Cardiology.

[57]  S. Yusuf,et al.  Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. , 1996, The American journal of cardiology.

[58]  G. Felker,et al.  Inotropes in the management of acute heart failure , 2008, Critical care medicine.

[59]  A. Fiorelli,et al.  [II Brazilian Guidelines for Cardiac Transplantation]. , 2010, Arquivos brasileiros de cardiologia.

[60]  M. Nieminen,et al.  Randomized study on safety and effectiveness of levosimendan in patients with left ventricular failure after an acute myocardial infarct , 1999 .

[61]  A. Yan,et al.  Narrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials , 2005, Annals of Internal Medicine.

[62]  M. Domanski,et al.  The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. , 2000, Journal of the American College of Cardiology.

[63]  D. Annane,et al.  Placebo-controlled, randomized, double-blind study of intravenous enalaprilat efficacy and safety in acute cardiogenic pulmonary edema. , 1996, Circulation.

[64]  A L Waldo,et al.  A comparison of rate control and rhythm control in patients with atrial fibrillation. , 2002, The New England journal of medicine.

[65]  W. Abraham,et al.  Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. , 1998, Journal of cardiac failure.

[66]  W. Kannel,et al.  The natural history of congestive heart failure: the Framingham study. , 1971, The New England journal of medicine.

[67]  H. Krumholz,et al.  Spectrum of heart failure in older patients: results from the National Heart Failure project. , 2002, American heart journal.

[68]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[69]  F. Sarullo,et al.  Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study. , 2005, Journal of the American College of Cardiology.

[70]  C. Hamm,et al.  Relation of N-terminal pro-B-type natriuretic peptide to severity of valvular aortic stenosis. , 2004, The American journal of cardiology.

[71]  Christoph Lehner,et al.  Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure. , 2003, Clinical science.

[72]  B. Massie,et al.  Nesiritide and worsening of renal function: the emperor's new clothes? , 2005, Circulation.

[73]  W. Kannel,et al.  Vital epidemiologic clues in heart failure. , 2000, Journal of clinical epidemiology.

[74]  C. Camargo,et al.  The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. , 2005, The American journal of cardiology.

[75]  R. McKelvie,et al.  Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. , 2002, Journal of the American College of Cardiology.

[76]  R. Starling,et al.  Sodium nitroprusside for advanced low-output heart failure. , 2008, Journal of the American College of Cardiology.

[77]  P. Poole‐Wilson,et al.  Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. , 1993, British heart journal.

[78]  William T. Abraham,et al.  Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness , 2005 .

[79]  L. Kritharides,et al.  Type of liver dysfunction in heart failure and its relation to the severity of tricuspid regurgitation. , 2002, The American journal of cardiology.

[80]  Paul G Shekelle,et al.  Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. , 2003, Journal of the American College of Cardiology.

[81]  N. Ayas,et al.  Does this dyspneic patient in the emergency department have congestive heart failure? , 2005, JAMA.

[82]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[83]  K. Adams,et al.  In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, Journal of the American College of Cardiology.

[84]  Lawrence Joseph,et al.  β-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis , 2001 .

[85]  I. Velasco,et al.  Hypertonic saline solution for prevention of renal dysfunction in patients with decompensated heart failure. , 2013, International journal of cardiology.

[86]  M. Esler,et al.  Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. , 2001, Journal of the American College of Cardiology.

[87]  U. Elkayam,et al.  Vasodilators in the management of acute heart failure. , 2008, Critical care medicine.

[88]  S. Aydoǧdu,et al.  Plasma brain natriuretic peptide levels in patients with rheumatic heart disease , 2004, European journal of heart failure.

[89]  G. Navis,et al.  Impaired renal function in patients with ischemic and nonischemic chronic heart failure: association with neurohormonal activation and survival. , 2004, American heart journal.

[90]  M. Nieminen,et al.  Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. , 2000, Journal of the American College of Cardiology.

[91]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[92]  J. Rouleau,et al.  Role of endothelins in congestive heart failure. , 2003, Canadian journal of physiology and pharmacology.

[93]  E. Bocchi,et al.  Exhaled acetone as a new biomaker of heart failure severity. , 2012, Chest.

[94]  A. Kastrati,et al.  Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction. , 2005, The American journal of cardiology.

[95]  M. Guglin,et al.  Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. , 2007, Journal of the American College of Cardiology.

[96]  W John Boscardin,et al.  Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. , 2005, JAMA.

[97]  Luigi Tavazzi,et al.  Acute Heart Failure Syndromes: Current State and Framework for Future Research , 2005, Circulation.

[98]  M. Guglin,et al.  Patient selection for ventricular assist devices: a moving target. , 2013, Journal of the American College of Cardiology.

[99]  M. Cucherat,et al.  Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies--CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. , 2002, American heart journal.

[100]  A. John Camm,et al.  Atrial fibrillation and heart failure: natural history and pharmacological treatment. , 2004, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[101]  A. Mebazaa,et al.  Acute heart failure syndromes: clinical scenarios and pathophysiologic targets for therapy , 2007, Heart Failure Reviews.

[102]  T. LeJemtel,et al.  Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. , 2002, American heart journal.

[103]  R. Schrier.  Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1) , 1988, The New England journal of medicine.

[104]  J. Murabito,et al.  Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality The Framingham Heart Study , 2003, Circulation.

[105]  V. Somers,et al.  Dopamine and congestive heart failure: pharmacology, clinical use, and precautions. , 1999, Congestive heart failure.

[106]  K. Anstrom,et al.  Ultrafiltration in decompensated heart failure with cardiorenal syndrome. , 2012, The New England journal of medicine.

[107]  P. Armstrong,et al.  Renal Insufficiency and Heart Failure: Prognostic and Therapeutic Implications From a Prospective Cohort Study , 2004, Circulation.

[108]  T. Douglas Bradley,et al.  Sleep Apnea and Heart Failure: Part I: Obstructive Sleep Apnea , 2003, Circulation.

[109]  L. Bongartz.  The Severe Cardiorenal Syndrome , 2011 .

[110]  H. Krum,et al.  Demographics and concomitant disorders in heart failure , 2003, The Lancet.

[111]  J. Cleland,et al.  Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial , 2002, The Lancet.

[112]  M. Drazner,et al.  Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. , 2001, Journal of the American College of Cardiology.

[113]  E. Kaluski,et al.  Hemodynamic monitoring in acute heart failure , 2008, Critical care medicine.

[114]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[115]  B V Howard,et al.  The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. , 2001, Journal of the American College of Cardiology.